China Intelligent Connected Health Innovation Summit to Be Held in Shanghai on December 27, Featuring 3 Key Areas and 12 Thematic Sessions

The 2018 China Smart Connected Health Innovation Summit will be held on December 27 at the BFC Bund Finance Center in Shanghai. The conference is organized byFosun Pharma, VCBeatCo-hosted under the theme “New Trends, New Layouts,” bringing together participants fromListed Companies, Innovative and Entrepreneurial Enterprises, Experts and Scholars17 guests, coveringInternet+ Smart Hospitals, Health Big Data Empowerment and AI, Health Insurance & Health ManagementFocusing on Three Hot Sectors in the Healthcare Industry, a Brand Summit for Medical and Health Technology Innovation with 120 Attendees Will Be Held.

In 2018, the healthcare industry underwent profound and far-reaching innovative transformations. With the promulgation of new policies, internet hospitals gained significant momentum, empowered by smart technologies. The field of AI-powered medical imaging experienced an explosive boom, attracting a frenzy of capital inflows totaling RMB 10 billion. As a foundational supporting technology, big data has become an indispensable force driving industrial change. Health insurance broke through from the periphery of innovation into the public spotlight. The health management sector saw substantial market growth, with its size projected to reach RMB 203.9 billion by 2020. While 2018 marked a new phase of development for the healthcare industry, where do future opportunities truly lie beneath this massive tide? And what path should industry practitioners take?

Upholding its brand philosophy of “Continuous Innovation, Joyful Health,” Fosun Pharma drives the development of its products and services through technological innovation. As a leading enterprise in the industry, Fosun Pharma has partnered with VCBeat, an observer and recorder of the healthcare sector, to host the China Smart Connected Health Innovation Summit. The summit aims to foster greater exchange of perspectives and critical thinking within the industry, explore new pathways for innovative transformation in healthcare, and facilitate the implementation of novel business models.

17 industry leaders, including executives of listed healthcare companies, heads of innovative enterprises, and experts and scholars, will participate in the summit.

(No particular order)

Three Most Watched Sectors in the Healthcare Industry: Keynote Speeches, Roundtable Discussions, and Focus Dialogues to Map Out the Development Path of the Healthcare Industry.

Fosun Pharma is committed to becoming a leading enterprise in mainstream global healthcare markets, with three core business segments currently.Pharmaceutical Manufacturing and R&D, Medical Services, Medical Devices and Diagnostics. According to the third-quarter 2018 report released,The company achieved operating revenue of RMB 18.142 billion, representing a year-on-year increase of 39.99%.Net cash flow from operating activities amounted to RMB 2.088 billion, representing a year-on-year increase of 21.15%. The Company has continued to ramp up its R&D investment. From January to September 2018, Fosun Pharma’s R&D expenses totaled RMB 1.114 billion, a year-on-year increase of 59.13%; R&D expenses for the third quarter of 2018 reached RMB 405 million, up 69.65% year on year. Meanwhile, Fosun Pharma has continued to strengthen its presence in the field of innovative drugs, particularly by increasing R&D spending on monoclonal antibody biologics and biosimilars, small-molecule innovative drugs, and products undergoing consistency evaluation. Its independently developed innovative drug, Artesun® (artesunate for injection), is currently the only treatment for severe malaria that has received prequalification from the World Health Organization, with cumulative global sales exceeding 100 million vials. As an enterprise that grew out of Shanghai, Fosun Pharma has been actively exploring various forms of international cooperation, leveraging technological innovation to enhance its products and services. In 2017, it completed the acquisitions of Gland Pharma and Tridem Pharma, accelerating its internationalization process. It is believed that the China Smart Interconnected Health Innovation Summit hosted by Fosun Pharma—which takes innovation as the core driver of corporate development and adheres to an open, multi-win innovation mechanism—will provide more directional indicators for enterprises in the industry and promote the innovative development of the healthcare sector.

The Future Is Here: To Grasp the Big Picture, Observe Emerging Trends and New Strategic Layouts

Event Registration Link:http://hdxu.cn/Mx3xO

Limited to 120 attendees; free admission to the summit.